These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

514 related items for PubMed ID: 29396092

  • 1. Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial.
    Kantarjian HM, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A, Gaidano G, Wiktor-Jedrzejczak W, Carpenter N, Mehta B, Franklin J, Giagounidis A.
    Lancet Haematol; 2018 Mar; 5(3):e117-e126. PubMed ID: 29396092
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
    Mittelman M, Platzbecker U, Afanasyev B, Grosicki S, Wong RSM, Anagnostopoulos A, Brenner B, Denzlinger C, Rossi G, Nagler A, Garcia-Delgado R, Portella MSO, Zhu Z, Selleslag D.
    Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy.
    Fenaux P, Muus P, Kantarjian H, Lyons RM, Larson RA, Sekeres MA, Becker PS, Orejudos A, Franklin J.
    Br J Haematol; 2017 Sep; 178(6):906-913. PubMed ID: 28616874
    [Abstract] [Full Text] [Related]

  • 6. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.
    Tarantino MD, Bussel JB, Blanchette VS, Despotovic J, Bennett C, Raj A, Williams B, Beam D, Morales J, Rose MJ, Carpenter N, Nie K, Eisen M.
    Lancet; 2016 Jul 02; 388(10039):45-54. PubMed ID: 27103127
    [Abstract] [Full Text] [Related]

  • 7. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
    Oliva EN, Alati C, Santini V, Poloni A, Molteni A, Niscola P, Salvi F, Sanpaolo G, Balleari E, Germing U, Fenaux P, Stamatoullas A, Palumbo GA, Salutari P, Impera S, Avanzini P, Cortelezzi A, Liberati AM, Carluccio P, Buccisano F, Voso MT, Mancini S, Kulasekararaj A, Morabito F, Bocchia M, Cufari P, Spiriti MA, Santacaterina I, D'Errigo MG, Bova I, Zini G, Latagliata R.
    Lancet Haematol; 2017 Mar 02; 4(3):e127-e136. PubMed ID: 28162984
    [Abstract] [Full Text] [Related]

  • 8. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
    Dodillet H, Kreuzer KA, Monsef I, Skoetz N.
    Cochrane Database Syst Rev; 2017 Sep 30; 9(9):CD009883. PubMed ID: 28962071
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial.
    Lee JW, Lee SE, Jung CW, Park S, Keta H, Park SK, Kim JA, Oh IH, Jang JH.
    Lancet Haematol; 2019 Nov 30; 6(11):e562-e572. PubMed ID: 31474546
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia.
    Tarantino MD, Bussel JB, Blanchette VS, Beam D, Roy J, Despotovic J, Raj A, Carpenter N, Mehta B, Eisen M.
    Haematologica; 2019 Nov 30; 104(11):2283-2291. PubMed ID: 30846500
    [Abstract] [Full Text] [Related]

  • 19. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes.
    Sekeres MA, Kantarjian H, Fenaux P, Becker P, Boruchov A, Guerci-Bresler A, Hu K, Franklin J, Wang YM, Berger D.
    Cancer; 2011 Mar 01; 117(5):992-1000. PubMed ID: 20945323
    [Abstract] [Full Text] [Related]

  • 20. Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes.
    Sekeres MA, Giagounidis A, Kantarjian H, Mufti GJ, Fenaux P, Jia C, Yang AS, Platzbecker U.
    Br J Haematol; 2014 Nov 01; 167(3):337-45. PubMed ID: 25039607
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.